scholarly journals Editorial Comment to Nonmetastatic castration‐resistant prostate cancer treated with salvage focal brachytherapy after external beam radiotherapy

2021 ◽  
Vol 4 (4) ◽  
pp. 230-231
Author(s):  
Yukiyoshi Hirayama ◽  
Taro Iguchi
Keyword(s):  
Prostate Cancer ◽  
Editorial Comment ◽  
External Beam Radiotherapy ◽  
External Beam ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant

Long-term outcomes of definitive external-beam radiotherapy for non-metastatic castration-resistant prostate cancer

2018 ◽  
Vol 23 (4) ◽  
pp. 749-756 ◽  
Author(s):  
Rihito Aizawa ◽  
Kenji Takayama ◽  
Kiyonao Nakamura ◽  
Takahiro Inoue ◽  
Takashi Kobayashi ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
External Beam Radiotherapy ◽  
External Beam ◽  
Castration Resistant Prostate Cancer ◽  
Long Term Outcomes ◽  
Castration Resistant

scholarly journals Predictors of castration-resistant prostate cancer after dose-escalated external beam radiotherapy

The Prostate ◽  
2014 ◽  
Vol 75 (2) ◽  
pp. 175-182 ◽  
Author(s):  
Daniel E. Spratt ◽  
Zachary S. Zumsteg ◽  
Xin Pei ◽  
Paul B. Romesser ◽  
Josh Yamada ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
External Beam Radiotherapy ◽  
External Beam ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant

A meta-analysis on individual data of bone-targeting radio-isotopes in men with bone metastases from castration-resistant prostate cancer.

2018 ◽  
Vol 36 (6_suppl) ◽  
pp. 352-352
Author(s):  
Safae Aarab Terrisse ◽  
Chris C. Parker ◽  
Karamouza Eleni ◽  
A. Oliver Sartor ◽  
Nicholas James ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Bone Metastases ◽  
Meta Analysis ◽  
External Beam Radiotherapy ◽  
Rank Test ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant ◽  
Radium 223 ◽  
Significant Difference ◽  
Radio Isotopes

352 Background: Among bone-targeted radio-isotopes (RI), Radium-223 (an α-emitter) is the only one with clearly demonstrated overall survival (OS) benefit in men with castration-resistant prostate cancer (CRPC). The aim of this meta-analysis is to estimate the OS impact of RI in men with CRPC. Methods: An individual patient data meta-analysis was carried out from randomized trials with inclusion period 1993-2013. Eligible trials included more than 50 patients, mandated bone metastases from CRPC and randomly evaluated RI. Endpoints were OS (primary), symptomatic skeletal events (SSE) and toxicity. A fixed-effect model was used. The log-rank test stratified by trial was used to estimate individual and overall hazard ratios (HR). Subset analyses were performed by the type of radiation (α vs. β emission) and by trial comparison: RI + Chemotherapy (CT) vs. CT, RI+ External beam radiotherapy (EBRT) vs. EBRT, RI vs. EBRT. Results: From 9 identified trials, data from 6 trials comprising 2081 patients (min: 64, max: 921) were collected with 2 trials representing 80% of data. The data from 3 trials (n = 341) were not available. The overall effect on OS favoured RI with HR = 0.86 [0.77-0.95] but high heterogeneity between trials (p < 0.001, I2= 79.6%). The overall effect of α- emitters on OS (HR = 0.70 [0.58; 0.83], 2 trials, n = 985) significantly differed from that of β-emitters (HR = 0.96 [0.84; 1.10], n = 4 trials, n = 1096) (interaction p = 0.0041). The overall effect on SSE favoured RI with HR = 0.81 [0.69-0.93] (4 trials, n = 1806) with marked between trial heterogeneity (p = 0.08, I² = 55.3%) and a significant difference (p = 0.02) by the type of RI (α-emitters: HR = 0.65 [0.52-0.82]-2 trials, β-emitters: HR = 0.93 [0.77-1.13]-2 trials). Conclusions: In men with metastatic CRPC a significant improvement of OS and SSE was obtained with bone targeted α-emitter radio isotopes, but not with β-emitter. However, some between trial heterogeneity of effects on OS need further investigations.

Sign in / Sign up

Export Citation Format

Share Document